ADORA2A and neoplasm: Another clinical study has demonstrated that a high-affinity and selective A2AR inhibitor, ZM241385, in combination with anti-CTLA-4 mAb inhibited tumor growth and enhanced antitumor immune responses in a B16F10 mouse melanoma model [220,221].